The Global Fund and partners began rolling out PlusLife MiniDock Ultra near point-of-care TB test systems across 13 countries using $50 million from the Children’s Investment Fund Foundation. The rollout is designed to extend fast molecular testing capacity to settings where traditional lab turnaround times can limit timely diagnosis. PlusLife’s MiniDock Ultra is positioned for decentralized deployment, aiming to support programmatic TB control through earlier detection and improved patient management decisions. The multi-country start indicates an emphasis on scaling diagnostic infrastructure rather than limited pilot studies. The funding signal matters for manufacturers and diagnostics ecosystem partners, since it ties support to operational rollouts spanning multiple national health systems. As the systems move into integration, health authorities are expected to follow country-specific logistics and quality-assurance workflows to sustain performance at scale.